Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - The company faced challenges such as implanting centers not completing required training and software updates for claims processing not being effective until July 1, 2025, which hindered billing for procedures [7]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price plummeted by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3][4]. - The company previously claimed that its clinical data indicated a superior clinical benefit and differentiation of sonelokimab compared to competitors [4]. Group 3: Clinical Trial Results - The Phase 3 VELA trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Freeport-McMoRan Inc. is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia, which manages the Grasberg Copper and Gold Mine [4]. Allegations - The lawsuit alleges that Freeport overstated its commitment to safety, as unsafe mining practices at the Grasberg mine were likely to result in worker fatalities [5]. Stock Performance - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - On September 24, 2025, after an update on the incident revealed two fatalities and operational suspensions, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, indicated that the landslide was preventable, further impacting investor confidence [9].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% decline year-over-year. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Customer Dynamics - The lawsuit alleges that while Synopsys claimed its customers relied on its IP to minimize integration risk and speed time to market, the reality was that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. Stock Market Reaction - Following the release of disappointing Q3 2025 financial results, Synopsys's stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the United States and Canada [4]. Allegations and Stock Impact - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, attributing sales to sustainable customer demand rather than inventory loading by channel partners, which is indicative of fraudulent channel stuffing [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6]. Legal Proceedings - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois, with the lawsuit captioned Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3].

Core Viewpoint - A class action lawsuit has been filed against Gauzy Ltd. for securities fraud, alleging that the company made misleading statements and failed to disclose material adverse facts about its financial condition and operations during the specified class period [1][5]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case name Duong v. Gauzy Ltd., and covers individuals and entities that purchased Gauzy securities between March 11, 2025, and November 13, 2025 [1][2]. - Investors have a 60-day window from the notice date to move the court to serve as lead plaintiff in the action [2][6]. Company Financial Issues - On November 14, 2025, Gauzy announced that the Commercial Court of Lyon, France, ordered insolvency proceedings for three of its subsidiaries, which could lead to a default under the company's senior secured debt facilities [3][5]. - The company will not release its third-quarter financial results as previously planned due to these proceedings [3]. Market Reaction - Following the announcement of the insolvency proceedings, Gauzy's share price dropped by $2.00, or 49.8%, closing at $2.02 per share on November 17, 2025, with unusually high trading volume [4]. Allegations in the Lawsuit - The complaint alleges that Gauzy's management made materially false and misleading statements and failed to disclose that three subsidiaries were unable to meet their debts, leading to the likelihood of insolvency proceedings and potential defaults on debt facilities [5].

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GAUZY LTD. (GAUZ), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Happened? On November 14, 2025, before the market opened, Gauzy announced "the Commercial Court of Lyon, France, ordered the commencement of French ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alexander & Baldwin, Inc. (NYSE: ALEX) to MW Group and funds affiliated with Blackstone Real Estate and DivcoWest for $21.20 per share in cash is fair to A&B shareholders. Halper Sadeh encourages A&B shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The inve ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals made materially false and misleading statements regarding its prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the progress made with its therapeutic candidates and the quality of its supply chain and partners [3]. - As a result of these misstatements, the company's statements about its business, operations, and prospects were deemed materially false and misleading [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to stock inflation [5].